The effect of Quikclot® on foot ulcer patients who take anti-coagulants - a Pilot study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0003894

Enrollment

Registered

2019-05-08

Start date

2016-03-31

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : a. Materials and Subjects Experimental group: Quikclot Subjects: Patients with aspirin, clopidrogrel or Coumadin who were taking more than one month b. Assessment of primary ulcers:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults over 19 years of age who fully understood and agreed to this study agreement, 2. Patients undergoing outpatient and outpatient treatment with foot ulcers 3. Ulcers with a foot ulcer size less than 25 cm2 4. Wagner stage 1, 2 ulcers 5. Patients currently taking oral clopidrogrel and coumadin for more than 1 month

Exclusion criteria

Exclusion criteria: 1. Patients who do not agree with this study 2. Bone-exposed Wagner stage 3 or more ulcers 3. Patients whose ulcer size exceeds 25 cm2 4. Any person deemed unsuitable for this study at the discretion of the other investigator.

Design outcomes

Primary

Measure	Time frame
Evaluation of bleeding after 5 minutes and 10 minutes compression after curettage	—

Secondary

Measure	Time frame
Measurement of secondary skin reaction around the wound (redness, urticaria, itching, etc.)	—

Countries

Korea, Republic of

Contacts

Public ContactSEUNG HWAN HAN

Yonsei University Health System, Gangnam Severance Hospital

osmedic@yuhs.ac+82-2-2228-2180

Outcome results